{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:22:35Z","timestamp":1783650155639,"version":"3.55.0"},"reference-count":28,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["842001005"],"award-info":[{"award-number":["842001005"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2019,8,19]]},"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Our study presents findings on a previously developed standard set of clinical outcome data for pulmonary sarcoidosis patients. We aimed to assess whether changes in outcome varied between the different centres and to evaluate the feasibility of collecting the standard set retrospectively.<\/jats:p><jats:p>This retrospective observational comparative benchmark study included six interstitial lung disease expert centres based in the Netherlands, Belgium, the UK and the USA. The standard set of outcome measures included 1) mortality, 2) changes in pulmonary function (forced vital capacity (FVC), forced expiratory volume in 1\u2005s, diffusing capacity of the lung for carbon monoxide), 3) soluble interleukin-2 receptor (sIL-2R) change, 4) weight changes, 5) quality-of-life (QoL) measures, 6) osteoporosis and 7) clinical outcome status (COS). Data collection was considered feasible if the data were collected in \u226580% of all patients.<\/jats:p><jats:p>509 patients were included in the retrospective cohort. In total six patients died, with a mean survival of 38\u00b123.4\u2005months after the diagnosis. Centres varied in mean baseline FVC, ranging from 110 (95% CI 92\u2013124)% predicted to 99 (95% CI 97\u2013123)% pred. Mean baseline body mass index (BMI) of patients in the different centres varied between 27 (95% CI 23.6\u201329.4)\u2005kg\u00b7m<jats:sup>\u22122<\/jats:sup>and 31.8 (95% CI 28.1\u201335.6) kg\u00b7m<jats:sup>\u22122<\/jats:sup>. 310 (60.9%) patients were still on systemic therapy 2\u2005years after the diagnosis. It was feasible to measure mortality, changes in pulmonary function, weight changes and COS. It is not (yet) feasible to retrospectively collect sIL-2R, osteoporosis and QoL data internationally.<\/jats:p><jats:p>This study shows that data collection for the standard set of outcome measures for pulmonary sarcoidosis was feasible for four out of seven outcome measures. Trends in pulmonary function and BMI were similar for different hospitals when comparing different practices.<\/jats:p>","DOI":"10.1183\/23120541.00094-2019","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T17:36:22Z","timestamp":1572456982000},"page":"00094-2019","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes"],"prefix":"10.1183","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8789-3291","authenticated-orcid":false,"given":"Nynke A.","family":"Kampstra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"van der Nat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea M.","family":"Dijksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frouke T.","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta A.","family":"Renzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-3497","authenticated-orcid":false,"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Kouranos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Zanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus J.C.","family":"Eijkemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douwe H.","family":"Biesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"van der Wees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"2024101707265327000_5.4.00094-2019.1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12886-017-0667-0","article-title":"Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals","volume":"17","author":"Michelotti","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"2024101707265327000_5.4.00094-2019.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1011024"},{"key":"2024101707265327000_5.4.00094-2019.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1511701"},{"key":"2024101707265327000_5.4.00094-2019.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2013.01.018"},{"key":"2024101707265327000_5.4.00094-2019.5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ecco-jcc\/jjx161","article-title":"Developing a standard set of patient-centred outcomes for inflammatory bowel disease \u2013 an international, cross-disciplinary consensus","volume":"12","author":"Kim","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2024101707265327000_5.4.00094-2019.6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.amjcard.2018.02.037","article-title":"Defining and measuring a standard set of patient-relevant outcomes in coronary artery disease","volume":"121","author":"Daeter","year":"2018","journal-title":"Am J Cardiol"},{"key":"2024101707265327000_5.4.00094-2019.7","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman","year":"2011","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024101707265327000_5.4.00094-2019.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000394"},{"key":"2024101707265327000_5.4.00094-2019.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.10"},{"key":"2024101707265327000_5.4.00094-2019.10","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.lpm.2012.03.019","article-title":"Pulmonary manifestations of sarcoidosis","volume":"41","author":"Baughman","year":"2012","journal-title":"Presse Med"},{"key":"2024101707265327000_5.4.00094-2019.11","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.1999.14d02.x"},{"key":"2024101707265327000_5.4.00094-2019.12","first-page":"39","article-title":"Standardized lung function testing","volume":"19","author":"Quanjer","year":"1983","journal-title":"B Eur Physiopath Res"},{"key":"2024101707265327000_5.4.00094-2019.13","unstructured":"National Quality Forum. Report from the National Quality Forum: eMeasure Feasibility Assessment. April 2013. www.qualityforum.org\/Publications\/2013\/04\/eMeasure_Feasibility_Assessment.aspx"},{"key":"2024101707265327000_5.4.00094-2019.14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.rmed.2017.11.010","article-title":"Endpoints in sarcoidosis: more like IPF or asthma?","volume":"138S","author":"Judson","year":"2018","journal-title":"Respir Med"},{"key":"2024101707265327000_5.4.00094-2019.15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000499","article-title":"Why do people die from pulmonary sarcoidosis?","volume":"24","author":"Kouranos","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"2024101707265327000_5.4.00094-2019.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00187410"},{"key":"2024101707265327000_5.4.00094-2019.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.07.008"},{"key":"2024101707265327000_5.4.00094-2019.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2569"},{"key":"2024101707265327000_5.4.00094-2019.19","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024101707265327000_5.4.00094-2019.20","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024101707265327000_5.4.00094-2019.21","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1196135"},{"key":"2024101707265327000_5.4.00094-2019.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.09.003"},{"key":"2024101707265327000_5.4.00094-2019.23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000441-200301000-00001","article-title":"Glucocorticoid-induced osteoporosis in patients with sarcoidosis","volume":"325","author":"Adler","year":"2003","journal-title":"Am J Med Sci"},{"key":"2024101707265327000_5.4.00094-2019.24","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20295"},{"key":"2024101707265327000_5.4.00094-2019.25","doi-asserted-by":"publisher","DOI":"10.1136\/thx.53.5.425"},{"key":"2024101707265327000_5.4.00094-2019.26","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2024101707265327000_5.4.00094-2019.27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1186\/s12913-018-3828-9","article-title":"Health outcomes measurement and organizational readiness support quality improvement: a systematic review","volume":"18","author":"Kampstra","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2024101707265327000_5.4.00094-2019.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2005.00605.x"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00094-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:00:17Z","timestamp":1740373217000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00094-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10,30]]},"published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1183\/23120541.00094-2019"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00094-2019","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}